Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial

Journal:

The Lancet Oncology

Published:

2025-09-02

DOI:

10.1016/s1470-2045(25)00300-6

Affiliations:

17

Authors:

20

Go to article

Institutions	Authors	Share
Medica Scientia Innovation Research (MedSIR), Spain	4.000000	0.20
Institute Gustave-Roussy (IGR), France	2.000000	0.10
University of Turin (UNITO), Italy	1.500000	0.08
San Luigi University Hospital, Italy	1.500000	0.08
La Paz University Hospital, UAM, Spain	1.000000	0.05
Assistance Publique-Hopitaux de Marseille (AP-HM), France	1.000000	0.05
Hospital Clinic of Barcelona, Spain	1.000000	0.05
Toulouse University Hospital (CHU-Toulouse), France	1.000000	0.05
Centre Oscar Lambret, France	1.000000	0.05
Bergonié Cancer Institute, France	1.000000	0.05
Hospital de la Santa Creu i Sant Pau, Spain	1.000000	0.05
Virgen del Rocío University Hospital, Spain	1.000000	0.05
La Fe University Hospital, Spain	1.000000	0.05
Hospital Universitario A Coruña (CHUAC), Spain	1.000000	0.05
Curie Institute, France	0.500000	0.03
University of Versailles Saint-Quentin-en-Yvelines (UVSQ), France	0.500000	0.03

Interested in Oncology and Carcinogenesis?